Immunotherapeutic Strategies in Cancer and Atherosclerosis-Two Sides of the Same Coin.

ABSTRACT: The development and clinical approval of immunotherapies has revolutionized cancer therapy. Although the role of adaptive immunity in atherogenesis is now well-established and several immunomodulatory strategies have proven beneficial in preclinical studies, anti-atherosclerotic immunotherapies available for clinical application are not available. Considering that adaptive immune responses are critically involved in both carcinogenesis and atherogenesis, immunotherapeutic approaches for the treatment of cancer and atherosclerosis may exert undesirable but also desirable side effects on the other condition, respectively. For example, the high antineoplastic efficacy of immune checkpoint inhibitors, which enhance effector immune responses against tumor cells by blocking co-inhibitory molecul

SUBMITTER: Nettersheim FS 

PROVIDER: S-EPMC8792753 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature